Abstract
Background: The most potent angiogenic factor is the vascular endothelial growth factor (VEGF), and CD34 is an endothelial antigen that has been used to highlight the microvasculature vessel density (MVD) as a direct marker of the degree of neoangiogenesis. In the present study we report that VEGF expression and its relationship with MVD, in poorly and well differentiated colon adenocarcinoma, in order to consider the possibility of using the correlation between both antibodies as a prognostic factor. Materials and Methods: Tumor sections were stained by immunohistochemistry for CD34 and VEGF. Results: The mean of VEGF and CD34 did not show any significant differences between both types of tumors. Conclusion: The conventional factors taken into consideration were not significantly related to the angiogenic factors examined, so we could affirm that the correlation of both markers could be useful as prognostic factor.
Keywords: Colon cancer, VEGF, CD34, angiogenesis, colon, adenocarcinoma
Current Chemical Biology
Title: Evaluation of Angiogenesis with the Expression of VEGF-C and CD34 in Human Colon Cancer
Volume: 3 Issue: 3
Author(s): Ana Maria Inda, Marcela Nilda Garcia, Laura Beatriz Andrini, Adriana Laura Garcia, Ayelen Fernandez Blanco, Cecilia Cristina Furnus, Susana Mercedes Galletti, Javier Brandoni, Jorge Guillermo Martinez, Guillermo Daniel Prat and Ana Lia Errecalde
Affiliation:
Keywords: Colon cancer, VEGF, CD34, angiogenesis, colon, adenocarcinoma
Abstract: Background: The most potent angiogenic factor is the vascular endothelial growth factor (VEGF), and CD34 is an endothelial antigen that has been used to highlight the microvasculature vessel density (MVD) as a direct marker of the degree of neoangiogenesis. In the present study we report that VEGF expression and its relationship with MVD, in poorly and well differentiated colon adenocarcinoma, in order to consider the possibility of using the correlation between both antibodies as a prognostic factor. Materials and Methods: Tumor sections were stained by immunohistochemistry for CD34 and VEGF. Results: The mean of VEGF and CD34 did not show any significant differences between both types of tumors. Conclusion: The conventional factors taken into consideration were not significantly related to the angiogenic factors examined, so we could affirm that the correlation of both markers could be useful as prognostic factor.
Export Options
About this article
Cite this article as:
Inda Maria Ana, Garcia Nilda Marcela, Andrini Beatriz Laura, Garcia Laura Adriana, Blanco Fernandez Ayelen, Furnus Cristina Cecilia, Galletti Mercedes Susana, Brandoni Javier, Martinez Guillermo Jorge, Prat Daniel Guillermo and Errecalde Lia Ana, Evaluation of Angiogenesis with the Expression of VEGF-C and CD34 in Human Colon Cancer, Current Chemical Biology 2009; 3 (3) . https://dx.doi.org/10.2174/2212796810903030302
DOI https://dx.doi.org/10.2174/2212796810903030302 |
Print ISSN 2212-7968 |
Publisher Name Bentham Science Publisher |
Online ISSN 1872-3136 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Overview of Systems Biology and Omics Technologies
Current Medicinal Chemistry Inhalable Nanostructures for Lung Cancer Treatment: Progress and Challenges
Current Nanomedicine Prospects for Plant-Derived Chemopreventive Agents Exhibiting Multiple Mechanisms of Action
Current Medicinal Chemistry - Anti-Cancer Agents Methotrexate-Induced Pneumonitis: Heterogeneity of Bronchoalveolar Lavage and Differences between Cancer and Rheumatoid Arthritis
Inflammation & Allergy - Drug Targets (Discontinued) Design Strategies, Structures and Molecular Interactions of Small Molecule Src Inhibitors
Anti-Cancer Agents in Medicinal Chemistry Body Fluids-Derived Exosomes: Paving the Novel Road to Lung Cancer Diagnosis and Therapy
Anti-Cancer Agents in Medicinal Chemistry Small Molecules Modulating Biogenesis or Processing of microRNAs with Therapeutic Potentials
Current Medicinal Chemistry MicroRNAs in Esophageal Adenocarcinoma: Functional Significance and Potential for the Development of New Molecular Disease Markers
Current Pharmaceutical Design Advances in the Researches on the Biological Activities and Inhibitors of Phosphatidylinositol 3-kinase
Anti-Cancer Agents in Medicinal Chemistry Enteral Administration of TKIs: Report of a Response to Ceritinib in an ALK-positive NSCLC Patient and Literature Review
Current Drug Targets Cancer Gene Therapy with Tissue Inhibitors of Metalloproteinases (TIMPs)
Current Gene Therapy Antitumor Activity of Copper (I)–Nicotinate Complex and Autophagy Modulation in HCC1806 Breast Cancer Cells
Anti-Cancer Agents in Medicinal Chemistry Lentiviral-Mediated Overexpression of MicroRNA-141 Promotes Cell Proliferation and Inhibits Apoptosis in Human Esophageal Squamous Cell Carcinoma
Recent Patents on Anti-Cancer Drug Discovery Airway Fibroblast Secretory Products Enhance Cell Migration
Current Proteomics Comparison of Efficacy and Peripheral Neuropathy of Solvent-based Paclitaxel with Paclitaxel Poliglumex and NK105: A Systematic Review and Metaanalysis
Current Pharmaceutical Design Molecular Classification of Breast Carcinoma In Situ
Current Genomics Nanostructural Hybrid Sensitizers for Photodynamic Therapy
Current Pharmaceutical Design Pharmacogenomics of Non-Small Cell Lung Cancer
Current Pharmacogenomics Nanosponges Encapsulated Phytochemicals for Targeting Cancer: A Review
Current Drug Targets TRPV1 Function in Health and Disease
Current Pharmaceutical Biotechnology